` MNKD (MannKind Corp) vs S&P 500 Comparison - Alpha Spread

MNKD
vs
S&P 500

Over the past 12 months, MNKD has underperformed S&P 500, delivering a return of -7% compared to the S&P 500's 12% growth.

Stocks Performance
MNKD vs S&P 500

Loading

Performance Gap
MNKD vs S&P 500

Loading
MNKD
S&P 500
Difference

Performance By Year
MNKD vs S&P 500

Loading
MNKD
S&P 500
Add Stock

Competitors Performance
MannKind Corp vs Peers

S&P 500
MNKD
ABBV
AMGN
GILD
VRTX
Add Stock

MannKind Corp
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

MannKind Corp. stands as a fascinating player in the biotech landscape, primarily due to its focus on innovative drug delivery systems that aim to redefine patient experience and therapeutic efficacy. Founded with the intention of creating transformative medicinal solutions, the company is best known for its flagship product, Afrezza, an inhalable form of insulin designed to manage diabetes. This unique delivery method not only enhances the speed at which insulin begins to act within the body, but also offers a discreet and user-friendly alternative to traditional injectable options. Driven by a blend of science and practicality, MannKind's efforts are centered around enhancing quality of life for patients, marking its territory in a niche, yet crucial, segment of the pharmaceutical market. MannKind generates revenue by producing and distributing its highly specialized products, leveraging partnerships with larger pharmaceutical companies to expand its market reach. By optimizing their drug delivery systems, they aim to position themselves competitively, offering solutions that stand out in a crowded industry. Beyond Afrezza, MannKind seeks to harness its proprietary Technosphere technology platform, exploring applications beyond diabetes to potentially treat other conditions. This approach not only broadens their market horizon but also diversifies potential revenue streams, allowing MannKind to maintain a steady course in the volatile currents of the biotech sector. In essence, MannKind's business strategy is a calculated blend of ingenuity and collaboration, with a clear emphasis on meeting unmet medical needs effectively.

MNKD Intrinsic Value
4.54 USD
Undervaluation 4%
Intrinsic Value
Price
Back to Top